TickerFacts.

Scinai Immunotherapeutics Ltd. (SCNI): Revenue

Annual figures by period end, from SEC filings.

$1.31M
Year ended 2025-12-31
2024-12-31: $658.0K2025-12-31: $1.31M$1.31M
2024-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$1.31M+99.2%2026-04-01, From 2025-01-01
2024-12-31$658.0Kn/a2026-04-01, From 2024-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$1.31M+99.2%
Inhibrx Biosciences, Inc. (INBX)2025-12-31$1.30M+550.0%
Outlook Therapeutics, Inc. (OTLK)2025-09-30$1.41Mn/a
Pluri Inc. (PLUR)2026-06-30$1.02M-24.0%
Prokidney Corp. (PROK)2025-12-31$893.0Kn/m
Humacyte, Inc. (HUMA)2025-12-31$2.04Mn/a
ImageneBio, Inc. (IMA)2025-12-31$800.0K-77.1%
Aligos Therapeutics, Inc. (ALGS)2025-12-31$2.19M-39.5%
Cardiff Oncology, Inc. (CRDF)2025-12-31$593.0K-13.2%

Compare SCNI, INBX, OTLK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗